

UCLA

UCLA Previously Published Works

Title

Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

Permalink

<https://escholarship.org/uc/item/2482v9xs>

Journal

Neuro-Oncology, 23(3)

ISSN

1522-8517

Authors

Chuntova, Pavlina
Chow, Frances
Watchmaker, Payal B
[et al.](#)

Publication Date

2021-03-25

DOI

10.1093/neuonc/noaa277

Peer reviewed

Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

Pavlina Chuntova[†], Frances Chow[†], Payal B. Watchmaker[†], Mildred Galvez[†], Amy B. Heimberger, Evan W. Newell, Aaron Diaz[◊], Ronald A. DePinho, Ming O. Li, E. John Wherry, Duane Mitchell, Masaki Terabe[◊], Derek A. Wainwright, Jay A. Berzofsky, Christel Herold-Mende, James R. Heath, Michael Lim, Kim A. Margolin, E. Antonio Chiocca, Noriyuki Kasahara, Benjamin M. Ellingson[◊], Christine E. Brown, Yvonne Chen, Peter E. Fecci, David A. Reardon, Gavin P. Dunn, Linda M. Liau, Joseph F. Costello[◊], Wolfgang Wick[◊], Timothy Cloughesy, William C. Timmer, Patrick Y. Wen, Robert M. Prins, Michael Platten, and Hideho Okada

Department of Neurological Surgery, UCSF, San Francisco, California (P.C., P.B.W., A.D., N.K., J.F.C., H.O.); Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California (F.C., T.C.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, Los Angeles, California (M.G., R.M.P.); Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.B.H.); Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.W.N.); Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas (R.A.D.); Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York (M.O.L.); Department of Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania (E.J.W.); Department of Neurosurgery, University of Florida College of Medicine, Gainesville, Florida (D.M.); Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (M.T., J.A.B.); Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois (D.A.W.); Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany (C.H.-M.); Institute for Systems Biology, Seattle, Washington (J.R.H.); Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland (M.L.); Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California (K.A.M.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (E.A.C.); Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (B.M.E.); Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, California (C.E.B.); Department of Microbiology, Immunology & Molecular Genetics, UCLA, Los Angeles, California (Y.C.); Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina (P.E.F.); Department of Medicine/Medical Oncology, Harvard Medical School, Boston, Massachusetts (D.A.R.); Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri (G.P.D.); Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California (L.M.L.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (W.C.T.); Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (P.Y.W.); Parker Institute for Cancer Immunotherapy, San Francisco, California (R.M.P., H.O.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); DKTK CCU Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (M.P.); Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany (W.W.)

Corresponding Authors: Robert M. Prins, PhD, Department of Neurosurgery, University of California, Los Angeles, Box 956901, 300 Stein Plaza, Suite 562, Los Angeles, CA 90095, USA (RPrins@mednet.ucla.edu); Micheal Platten, MD, PhD, CCU Brain Tumor Immunology, German Cancer Research Center, INF 280, Heidelberg, Germany, D-69120 (m.platten@Dkfz-Heidelberg.de); Hideho Okada, MD, PhD, Department of Neurological Surgery, University of California San Francisco, Parker Institute for Cancer Immunotherapy, HD 472 1450 3rd Street San Francisco, CA 94158, USA (hideho.okada@ucsf.edu).

[†]These authors contributed equally to this work.

Abstract

Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell-engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights into the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells, T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner.

Keywords

clinical trial | conference report | glioblastoma | immunosuppression | immunotherapy

Immunotherapy of cancer has advanced from an experimental stage to an established therapeutic pillar for many first- and second-line indications. In particular, humanized antibodies blocking the negative costimulatory molecules, cytotoxic T-lymphocyte-associated protein (CTLA)-4, programmed cell death (PD)-1, or its ligands, such as PD-L1, have revolutionized the treatment of many metastatic solid tumors. Current FDA approvals of immune checkpoint inhibitors, with companion biomarkers,¹ for the treatment of malignancies include melanoma, lung cancer, triple-negative breast cancer, bladder cancer, liver cancer, renal cell carcinoma, microsatellite instable colon cancer, and others. FDA approvals have also included chimeric antigen receptor (CAR)-transduced T cells targeting CD19 for refractory B-cell lymphoma and acute lymphoblastic leukemia.¹ Similarly, the use of bispecific T-cell-engaging antibodies targeting CD19 or antibody-drug conjugates targeting CD30 was recently granted FDA approval, and the FDA has granted more than 50 separate approvals to immune-based therapies since 2015 (<https://www.cancerresearch.org/scientists/immuno-oncology-landscape/fda-approval-timeline-of-active-immunotherapies>).

Although multiple cancer types have been successfully treated with immunotherapies, a notable exception includes primary malignant gliomas. Recent randomized clinical trials with PD-1 blockade in unselected O⁶-methylguanine-DNA methyltransferase (MGMT)-unmethylated newly diagnosed and recurrent glioblastoma (GBM),² vaccines targeting tumor-associated and tumor antigens,^{3,4} and replication-competent retrovirus administration⁵ have not demonstrated a clinical benefit in this patient population. To more effectively understand the resistance of GBM to immunotherapy and to foster inter-cancer collaborations, the authors hosted an Immuno-Oncology Think Tank Meeting at the 2019 Annual

Society for Neuro-Oncology Scientific Conference. Experts in the field of brain cancer were paired with other scientific experts whose expertise was extracranial cancer and/or fundamental immunology. In consultation with the organizing committee, the interdisciplinary sessions focused on the tumor microenvironment (TME), myeloid cells, T-cell dysfunction, other immune cell populations, immunomodulatory factors, targetable antigens, metastatic brain tumor differences, viral immunotherapies, imaging technologies, CAR-T adoptive transfer strategies, and clinical trial design. An overview from these sessions, as well as key points, is presented below. We also propose a roadmap for future immunotherapy research based on insights gained from this opportunity.

Immune Microenvironment of GBM

Studies of the GBM TME and tumor-infiltrating leukocytes (TILs) highlight the complex and immunosuppressive environment within the tumor that underlies the resistance to immunotherapy. Among these mechanisms are the release of immunosuppressive factors, recruitment of immunosuppressive cells, exclusion of anti-tumor immune effector cells, and expression of cell-surface inhibitory ligands.⁶ Relative to other cancers that have responded to immunotherapy, GBM has a lower frequency of CD3⁺T cells, a higher frequency of myeloid cells (monocytes, macrophages, microglia), and a lower expression of PD-L1 and lower prevalence of PD-1-expressing TILs.⁷⁻⁹ The lower T-cell infiltration and lower expression of inhibitory markers make it more challenging for immune checkpoint blockade in GBM to exert a strong therapeutic effect. In addition, macrophages found within GBM have a higher expression of phenotypic markers of immunosuppression and are

associated with poor survival, suggesting that improving immunotherapeutic interventions should include altering macrophage characteristics or abundance.^{7,10,11}

Poor Status of T Cells

Tumor-infiltrating leukocytes (TILs) constitute a small population of immune cells within the TME and represent a highly heterogeneous population. In GBM and other cancers, TILs include both cancer-specific cells and nonspecific bystanders.¹² To improve the efficacy of immunotherapy, it will be essential to distinguish bystander CD8⁺T cells from cancer-specific CD8⁺T cells.¹³ In lung and colorectal cancer, many of the CD8⁺TILs are specific for unrelated antigens, such as Epstein-Barr virus (EBV), cytomegalovirus (CMV), or influenza virus (flu).¹² Although these cancer-unrelated tumor-infiltrating T cells can express various markers associated with their active participation in an inflammatory response, such as PD-1, TIGIT, HLA-DR, and CD69, they consistently lack the expression of CD39,¹² which is an ectonucleotidase implicated as having immunosuppressive effects¹⁴ and expressed by chronically stimulated and terminally exhausted T cells.¹⁵ Similarly, GBM has virus-specific cells in the TME, with a notable enrichment of Influenza-specific T cells as compared with other tumor types and with other viral antigen specificities¹⁶ (Figure 1). As the presence of viral antigens in the GBM TME has not been supported by the Pan-Cancer Analysis of Whole Genomes (PCAWG),¹⁷ the role of virus-specific T cells in the TME remains unknown. Yet, their presence offers a potential source of tumor-targeting T cells.¹⁸

Among the challenges to effective immunotherapy include significant T-cell dysfunction, which can be attributed to poor T-cell infiltration into the tumor and the highly immunosuppressive nature of the TME.^{6,19} T-cell defects can be the result of *exhaustion* (hypofunctional state due to sustained expression of inhibitory receptors), *ignorance* (the absence of response due to either anatomical barriers or insufficient antigen presentation), *anergy* (an inactive

state following an antigen encounter), *tolerance* (programmed induction of unresponsiveness or deletion of T-cell clones to prevent autoimmunity), and *senescence* (a hypofunctional state resulting from shortened telomeres) (Figure 2).¹⁹ In addition, there are several metabolic factors that hinder T-cell function, such as tumor-induced nutrient competition and hypoxia.¹⁹

Tumor- or myeloid-mediated T-cell exclusion, poor access to the CNS, and poor T-cell priming due to high tumor diversity and few suitable antigens all likely contribute to the decreased infiltration of functional T cells.^{19,20} Each of these factors should be further investigated in order to elucidate the mechanisms and components contributing to this dysfunction. For example, further interrogation into the mechanisms of T-cell exclusion has revealed a role for remote organs. Naïve T cells have been shown to accumulate in the bone marrow of GBM patients and mice, which appears to be the result of tumor-mediated internalization of sphingosine-1-phosphate receptor 1 (S1P1) on T cells.²¹ In mouse models, blocking S1P1 internalization releases T cells and restores anti-tumor cytotoxicity, providing a possible avenue for therapeutic intervention. Likewise, the identification of common pathways in tumor-infiltrating T cells, which are excluded or suppressed by tumor-derived metabolites, such as kynurenine or 2-hydroxyglutarate,^{22,23} may result in therapeutic strategies to increase T-cell resilience and function.

In the context of persistent antigen stimulation, as seen in chronic infection or cancer, T cells are driven into a state of exhaustion, which is characterized by the loss of cytokine production and cytotoxicity.²⁴ This exhausted state is often mediated by transcriptional changes and epigenetic programming.²⁵ Tox, an HMG-box transcription factor, has been identified as a key regulator of CD8⁺T-cell exhaustion in mice.²⁵ Exhausted CD8 T cells also exhibit increased expression of inhibitory ligands, such as PD-1, which can be targeted via immune checkpoint blockade to reinvigorate T-cell activity and stimulate an anti-tumor immune response.¹⁹ Currently, it is not known what the antigenic targets of chronic T-cell reactivity are, but several groups are currently studying this concept.




Fig. 1 Bystander T cells in the tumor microenvironment. Schematic representation of the source and nature of T cells present in tumors. Tumors contain neoantigen-specific, tumor-specific, and viral-specific T cells that may be distinguished by CD39 expression. Concepts based on results are presented in Simoni et al.¹²




Fig. 2 Potential types of T-cell dysfunction relevant for neuro-oncology. Summary of the major factors contributing to T-cell dysfunction.

To leverage the benefits of immunotherapy, the mechanisms contributing to T-cell dysfunction in GBM need to be further explored. Questions yet to be answered should address the following: What are the key immunosuppressive pathways or cell types? How does priming to CNS antigens occur? What regulates immune cell homing to the brain? Addressing these questions requires a highly combinatorial and multifaceted approach which should include high dimensional immune profiling platforms, better preclinical models, and creative clinical trial design, such as neoadjuvant immunotherapies involving cell-based methods, checkpoint inhibitors, and immune enhancers.

Key Points

- GBM has poor T-cell infiltration, high myeloid infiltration, and low PD-L1/PD-1 expression
- A large subset of TILs are cancer nonspecific and are characterized by the lack of CD39 expression. TILs in GBM appear to be enriched for Influenza-specific T cells
- GBM patients have decreased T-cell numbers and functions both locally in the TME and systemically in the circulation
- T-cell dysfunction is attributed to exhaustion, ignorance, anergy, tolerance, senescence, and metabolic pressures

Myeloid Cells as Mediators of Immunosuppression and Tumor Progression

Myeloid cells represent the most abundant immune cell type infiltrating GBMs, where their content can range between 40% and 70% of the total cell population.^{26,27} These myeloid cells are a heterogeneous population with primarily tumor-promoting functions.^{11,28} Macrophage activation status has been shown to span a broad spectrum of phenotypes that are highly dependent on the stimuli present in a specific tissue microenvironment.¹¹ The paradigm defining macrophages as either classically activated anti-tumor M1

macrophages or immunosuppressive M2 macrophages provides points of reference; however, recent data indicate the differentiation of GBM-infiltrating macrophages is a continuous process, characterized by the large numbers of relatively immature myeloid cells that can express both canonical M1 and M2 markers at the same time.^{29,30} These cells are likely to contribute to the outcomes of GBM patients treated with immune therapies given their high abundance and immunosuppressive functions.

Recent studies have underscored the importance of cell ontogeny for the overall myeloid cell distribution and activation. Single-cell-based analyses by the Diaz lab demonstrated that, in contrast to microglia, blood-derived myeloid cells aggregate in distinct compartments within GBM tumors and associate with distinct GBM cell types.^{29,30} These findings indicate that despite being exposed to similar tumor environmental stimuli, myeloid cells retain functional differences based on programming defined by their progenitors. Differences also exist in the activation profiles of different myeloid populations.^{31,32} These findings suggest that myeloid cell responses in the context of targeted therapies are varied and their contributions to the tumor's adaptive resistance to treatment need to be considered.

A deeper understanding of the source and biological function of GBM-associated myeloid cells would also improve efforts to target them with greater specificity than achieved previously. Vascular endothelial growth factor (VEGF) produced by tumors has been found to induce the development of myeloid-derived suppressor cells (MDSCs) through mechanisms dependent on signal transducer and activator of transcription 3 (STAT3).³³ STAT-3 is a transcription factor known to promote tumorigenesis and facilitate T-cell dysfunction.¹¹ Activation of STAT3 in brain tumor-infiltrating macrophages has been demonstrated in both preclinical models and patient-derived samples.³⁴ Inhibiting STAT-3 in mice and in immune cells from GBM patients leads to a restoration of T-cell function and reversal of immune suppression mediated by macrophages and microglia.³⁴ In addition to STAT-3 inhibition, blockade

of VEGF or its receptor could overcome this immunosuppressive effect. These findings suggest that agents that reprogram the transcriptional signature and cellular interactions within the TME can increase the effectiveness of immunotherapies, such as vaccines and CAR-T adoptive transfer therapy.

As the largest number of infiltrating myeloid cells has been shown to be blood-derived, an opportunity is available to impact the polarization and homing of blood-circulating monocytes prior to their arrival at the tumor site, such as targeting chemokines.^{35,36} Immune-targeting therapies are often administered and exert their primary effect systemically. For example, the target of the intravenously injected anti-CD40 antibody has been shown to be predominantly circulating monocytes.³⁷ These monocytes were then able to traffic to nonlymphoid organs and induce differentiation of tissue-resident CD8⁺ T cells, which is a critical step in the development of long-lasting anti-tumor immunity. Elucidating more precisely the biological functions of tumor-associated myeloid cells provides further understanding of how these populations interact with additional lines of treatment, such as oncolytic viruses and adoptively transferred cytotoxic lymphocytes. Finally, such in-depth functional studies are likely to yield novel strategies for the therapeutic repolarization of GBM-associated myeloid cells, which might provide greater benefits than pan-myeloid depletion.

It is also important to recognize how the heterotypic relationship between tumor and myeloid cells impacts the evolution of tumors. Genetic and epigenetic variations within tumor cells affect not only the growth of the tumor cells themselves, but also how they interact with the stroma and immune components of TME. These broader effects can be surmised through empirical and unbiased systematic cross-species analyses of different tumor subtypes and their corresponding TME phenotypes. Given the reciprocal nature of these heterotypic interactions, applying pressure on one cell type through therapeutic interventions may affect the phenotype and function of the other. Recently, in models of *PTEN*-deficient GBM,³⁸ Chen et al. demonstrated that *PTEN* deficiency in GBM cells leads to upregulation of the potent macrophage chemoattractant lysyl oxidase (LOX) in a YAP-1-dependent manner. The LOX-dependent upregulation in β 1 integrin receptor signaling in blood-circulating monocytes drives their infiltration into GBM tissue where they acquire a tumor-associated macrophage (TAM) phenotype and promote GBM survival and angiogenesis via secretion of secreted phosphoprotein 1 (SPP1). Perturbation of these interactions through the inhibition of LOX signaling reduces TAM infiltration and inhibits tumor growth. This synthetic lethality approach offers a novel therapeutic target but is specific to a particular GBM genotype, underscoring the vast heterogeneity that exists within the TME. In addition, using a gain-of-function screen of epigenetic regulators, Chen et al. identified the circadian regulator *CLOCK* as a top hit that not only enhances stem-cell self-renewal and anabolic metabolism, but also recruits tumor-promoting microglia into the TME through *CLOCK*-mediated transcriptional upregulation of the novel chemokine *OLFML3*. In GBM models, depletion of *CLOCK* or *OLFML3* extends overall survival and reduces intratumoral microglia density.³⁹ Thus, a detailed and

systemic evaluation of the tumor cellular and molecular composition is warranted, both at diagnosis (and ideally, through the biopsy of multiple tumor locations) and in a longitudinal format if the mechanisms of adaptive resistance are to be revealed. Once such mechanisms are discovered through the use of ever-evolving model systems, careful consideration of the benefits and drawbacks of these models must be applied in order to generate successful and informative combination clinical trials.

The immunological TME of GBM warrants further study and should involve the definition of the distinct immune cell populations and their interactions. Questions to be addressed include: what are the key cell-cell interactions in the TME? What role can macrophages play in immunotherapy? What are the frequencies of tumor-specific T cells? What is attracting virus and particularly Influenza-specific T cells to the TME and can they be repurposed for immunotherapy? To address this, several methods should be employed to visualize and define the immune topographical landscape of GBM.

Key Points

- Macrophages are overrepresented in the glioma TME and are highly immunosuppressive
- It is necessary to determine how TAM activation and tumor distribution are guided by the ontogeny of the different myeloid cell types and by the underlying genetics of the tumor
- Perform empirical and unbiased systematic validation of TAM-targeting therapies (alone or in combination with other therapies) on both genetic and pharmacological levels to yield positive outcomes without high levels of systemic toxicity

Dendritic Cells

A critical step in the generation of a robust antigen-specific immune response is the interaction between professional antigen-presenting cells (APCs), which capture and present protein and lipid antigens, and CD8⁺ or CD4⁺ T cells. Dendritic cells (DCs) are well characterized for their ability to capture antigen, migrate to secondary lymphoid organs, and interact with cells of the adaptive arm of the immune system. Their role in the TME, however, is not fully understood. Studies from the Gajewski lab have demonstrated that the expression of the transcription factor, *Batf3*, in DCs is required for the recruitment of CD8⁺ effector T cells to the TME in a murine model of melanoma.⁴⁰ The role of DCs, and their ability to cross-present tumor antigens, may be even more crucial in the microenvironment of GBM given the absence of the afferent arm of the immune response in the brain parenchyma.⁴¹ Decades of studies in the fields of infection and CNS autoimmune disorders have shown that APCs are able to infiltrate the parenchyma and initiate antigen-specific immune responses.^{42,43} Given sufficient priming and recruiting chemokine gradients, APCs can traffic through the meninges, choroid plexus, and the blood-brain barrier (BBB), particularly when perturbations of the endothelial cell tight junctions of the BBB have occurred due to tumor growth.^{44,45} However, elucidating the key stages of tumor growth, when APCs exert their most

important anti-tumor immune function, remains a large gap in the community's understanding. Furthermore, developing strategies for the differentiation of myeloid cells, already present at the tumor site, into DCs, or alternatively, for the recruitment of DCs from the circulation, could significantly benefit the induction of a productive anti-tumor immune response. One such strategy might be to induce the production of Flt3L in the TME, using adenoviral-mediated gene delivery, resulting in the influx of DCs and brain tumor-specific immune response, as described by King and colleagues.⁴⁶ Alternatively, recent studies by the Mitchell lab demonstrated the possibility of using Lin-CCR2⁺ hematopoietic stem cells, which traffic to the intracranial tumor site and differentiate into mature DCs, to overcome resistance to immune checkpoint therapy.^{47,48} These results indicate that multiple routes are available for the generation of functional APCs at the tumor site, and their contributions to a productive anti-GBM immune response are likely important and significant.

A different aspect of APC function in tumor growth and development also needs to be considered. As professional APCs, DCs are known for their potent ability to prime naïve T cells and initiate an anti-tumor response in the periphery. However, as chronic antigen stimulation may result in T-cell exhaustion, the precise contribution of APCs to the development of T-cell dysfunction needs to be carefully examined. Within the glioma TME, multiple cell types can present antigens, including conventional DCs, TAMs, astrocytes, as well as the cancer cells themselves. In order to present tumor-derived antigens, cells need to employ either the more frequent mechanism of cross-presentation, where extracellular peptides/proteins are phagocytosed, processed endogenously, and cross-presented, or the lesser-known pathway of cross-dressing, where preformed antigen-class I major histocompatibility (MHC) molecules are transferred from one cell to another.⁴⁹ How these mechanisms operate within TAMs, which are the most abundant APC within tumors, is not well known, and elucidating their contribution to antigen presentation past the initial states of priming may reveal novel therapeutic opportunities. In order to study these pathways most efficiently, accurate model selection is critical as certain models better represent the mechanisms of antigen presentation than do others. Furthermore, cell-type-specific perturbations in those models would be necessary in order to more precisely define differences in the activity of the many different APCs. Those can be accomplished through the use of cell-specific *Cre* models or the temporal/spatial control of cell depletion through the use of diphtheria toxin receptor-engineered mouse strains. One such recent study, by the Li lab, employed the transgenic breast cancer model MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor T-antigen) crossed with several mouse lines carrying APC-specific perturbations. Through detailed characterization of the phenotypic changes in both APCs and T cells, the authors demonstrate that while IRF8-expressing DCs are critical for the initial priming of cytotoxic T cells, IRF8 expression in TAMs leads to CTL exhaustion. This effect was reversed, and tumor growth was suppressed following macrophage-specific IRF8 ablation (<https://www.biorxiv.org/content/10.1101/2020.03.12.989731v1>). These findings

were extended in human renal carcinoma samples, where a high score for IRF8 signature-expressing TAMs was highly associated with T-cell exhaustion markers and was a negative predictor of patients' long-term survival. These observations highlight the important contributions different APCs have and how heterogeneous these effects can be given the large spectrum of cells capable of performing antigen presentation.

Key Points

- The appropriate migration and differentiation of DCs within the TME is critical for the priming of antigen-specific T-cell responses. There is a need for developing strategies to this end
- The adoptive transfer of hematopoietic stem cells may enhance the migration and differentiation of DCs within the TME
- There is a need to understand the contributions of microglia and astrocytes to the process of antigen presentation in the context of GBM tumors
- Gene delivery of Flt3L and/or GM-CSF to the TME may be employed to enhance differentiation of monocytes into APCs or recruit additional APCs
- Whether and how different APC populations drive T-cell exhaustion is unknown
- Development of models that accurately recapitulate and allow for robust study of antigen presentation in glioma is needed

CD1d-Restricted Natural Killer T (NKT) Cells

NKT cells represent a diverse population of T-lineage lymphocytes which, unlike conventional T cells, recognize antigen presented by CD1d, an MHC class I-like molecule.⁵⁰ NKT-cell receptors recognize primarily glycolipids, such as α -galactosylceramide (α -GalCer) and sulfatide, and play significant roles in the regulation of tumor immunity in a highly context-dependent fashion. Different NKT subsets may recognize different antigens and mediate productive or suppressive immune responses against tumors. Tumor patients often present with a suppressed number of NKT cells, although the precise mechanisms leading to this are unknown. Studies by numerous research groups have reported that glycolipids are enriched in brain tumor samples and likely contribute significantly to the maintenance of GBM stem cells.⁵¹ In addition, expression of glucosylceramide synthase in GBM samples was shown to reduce the efficacy of temozolomide (TMZ) treatment by Giussani et al., thereby implicating glycolipids in mechanisms of resistance.⁵² Sulfatides present in myelin sheaths in the CNS and in some tumor cell membranes can activate immunosuppressive type II NKT cells that can promote tumor growth.⁵³ Despite the increasing volume of evidence indicating the important role of glycolipids in the tumorigenesis of GBM, very little is known about the precise quantitative and qualitative differences of the glycolipid composition of healthy and malignant glial tissues. Given this lack of in-depth understanding of the quantity and

distribution of NKT-cell antigens within brain tumors, NKT-cell activity in the TME remains unclear and presents a vast opportunity for therapeutic exploration.

Key Points

- A better understanding of glycolipid composition between healthy and malignant glial tissues as well as glycolipid synthesis pathways could be important for effective anti-tumor immune responses
- NKT cells are an understudied lymphocyte population that recognize lipid antigens and could play a role in the anti-tumor immune response. There is a need to understand the antigenic properties of these glycolipids for NKT-mediated recognition by the immune system
- Above approaches will likely need to be combined with other treatment modalities such as immune checkpoint blockade, vaccination, radiation therapy, and local chemotherapy

Prioritizing Immunosuppressive Molecular Factors to Target Therapeutically

Soluble factors should also be explored in the context of immunotherapy for GBM. Of interest are mediators of

immune suppression, such as indoleamine and tryptophan 2,3-dioxygenase (IDO, TDO) and transforming growth factor-beta (TGF- β).

IDO and TDO are tryptophan metabolizing enzymes with additional nonenzymatic functions⁵⁴ that are elaborated by mononuclear cells in the TME. In patients and mouse models, IDO and TDO are associated with decreased overall survival.^{55,56} In both humans and mice, IDO1 increases in the brain with advanced aging.⁵⁷⁻⁵⁹ This coincides with GBM occurrence, suggesting that aging-increased IDO1 effects should be studied in the context of patient treatment strategies. Patients might benefit from treatments combining IDO and/or TDO inhibition with immunotherapy, although recent studies in melanoma were negative.⁶⁰

TGF- β in the TME plays a role in several immune regulatory pathways. It has 3 isoforms that act on the same receptor but in different locations, and with varying effects on cancer.⁶¹ TGF- β 3 may be beneficial in some cancers, whereas isoforms 1 and 2 are immunosuppressive and support the tumor growth.⁶¹ TGF- β suppresses CD8⁺ T cells and helps activate regulatory T cells (Tregs), thereby promoting tumor immune escape.⁶² In a series of mouse studies, it was found that TGF- β blockade can markedly reduce tumor size, can synergize with vaccines, and that TGF- β 1/2 blockade, when combined with vaccine and anti-PD-1 therapy, can significantly increase survival.^{61,63,64} However, in recent studies of galunisertib, an oral TGF- β -inhibitor




Fig. 3 Interaction of cells and molecules as potential targets for immunotherapy. A large number of immunoregulatory cells, cell-surface molecules, and secreted cytokines and chemokines regulate the immune response to tumors and help define the tumor microenvironment. Effective immunotherapy with vaccines or adoptively transferred T cells will likely require overcoming many of these immunosuppressive agents. To block each one individually is a Herculean task, so we need to identify nodes at which these suppressive pathways intersect, to allow simultaneous inhibition of many of them. Transforming growth factor (TGF- β) may be one such node, as it plays a critical role in immune escape as it is able to suppress CD8⁺ T cells and activate regulatory T cells. TGF- β is made by many cells, including tumor cells, as well as myeloid-derived suppressor cells (MDSCs) when stimulated by interleukin (IL)-13 from type II natural killer T (NKT) cells. Type II NKT cells also inhibit protective type I NKT cells and make IL-13 that can induce M2 macrophages. All of these and the Tregs induced by TGF- β can inhibit CD8 anti-tumor T cells. Thus, TGF- β and the cells it acts upon are central to a complex circuitry involving several different cell types and cytokines, positioning TGF- β at the intersection of multiple immunosuppressive mechanisms that could be targeted simultaneously by blocking this one cytokine.

alone or in combination with radiochemotherapy⁶⁵ or lomustine⁶⁶ failed to show improved overall survival in patients with newly diagnosed or recurrent GBM. These negative results emphasize the need for thorough biomarker-driven combination therapy studies exploring the capability of TGF- β blockade to synergize with other immunotherapies (Figure 3).

Several soluble immune regulatory factors exist in the TME that can limit the effectiveness of immunotherapies. By characterizing these factors more extensively, the therapeutic benefits of treatments may be enhanced. Questions to be explored include: How does aging-increased IDO1 affect survival in elderly GBM patients? How do age-mediated changes contribute to the decreased immunotherapeutic efficacy in GBM patients? What are the key immune regulatory points in the TME? What is the role of TGF- β in responses to PD-1 blockade and other immunotherapies?

Key Points

- Immunosuppressive factors in the TME can be targeted in combination with immunotherapy to increase treatment effectiveness
- IDO and TDO are immunosuppressive and IDO1 increases with advanced aging. IDO1 effects should be studied in the context of patient treatment strategies
- TGF- β is immunosuppressive and its blockade synergizes with other immune treatments

Targetable Antigens and Molecular Signatures

Can Neoantigens Be Replaced by Tumor-Associated Antigens?

Most GBM tumors initially present with a low mutational burden, and the majority of neoantigens are the products of private mutations and are not consistently expressed between patients, resulting in an extremely low number of bona fide GBM-specific and widely targetable neoantigens.^{67,68} One possible solution is to use RNA-sequencing data and analyze further for potentially immunogenic, differentially expressed nonmutant genes. However, this approach is extremely laborious and is perhaps not the most optimal one. Newer methods, such as those presented by Dutoit et al. rely on mining and exploiting already published data, and generating additional information on the immunogenicity and HLA (human leukocyte antigen)-binding preferences of different peptides in GBM samples.⁶⁹⁻⁷¹ Alternatively, unbiased searches for immunogenic peptides can be performed through a proteomics-based method in tumor protein fractions that have previously been shown to induce activation of T cells in patients.^{72,73} These approaches require several key investigative steps to ensure the efficacy and safety of the proposed targets. To validate the immunogenicity of new GBM targets, new tumor-associated antigens (TAAs) need in-depth characterization. This characterization should

validate the expression and the level of immunogenicity by gauging the level of response to the same TAA in T cells derived from a large series of patients, and finally characterizing the reactivity of T cells derived from healthy donors against the proposed TAA. In cases where diagnoses and circumstances allow for the development of a personalized list of targets, single-cell RNA-sequencing data has been shown to be suitable for the identification of multiple TAAs in a single patient. Finally, clinical efforts evaluating newly discovered TAAs might benefit from more robustly selected patient populations. In particular, elucidating the preexisting levels of T-cell infiltration in patients' samples, as well as their clinical parameters (age, extent of tumor resection, etc.), might provide valuable information on whether patients are able to mount a significant immune response and potentially benefit from immunotherapy.

Key Points

- Exploit already generated and available data to combine with novel proteomics-based searches in order to expand the data set of GBM-relevant TAAs, thereby expanding the repertoire and understanding of the antigenic properties of TAAs in GBM
- Characterize the heterogeneity, frequency of TAA recognition, and safety profile of immunogenic TAAs
- Re-evaluate immunotherapy clinical trials for the expression, presentation, and recognition of well-characterized TAAs in order to develop more effective combination therapies
- Develop more robust selection criteria for patients entering immunotherapy clinical trials to assure patients are "immune-responsive"

Unraveling Molecular Signatures from Tumor Resections

Given the inability of current immunotherapeutic treatments to generate long-term stable responses, evaluation of the immune response to therapy on the molecular level will require subtler and more discerning approaches in situ. One example of an emerging new technology that is able to provide detailed proteomic and transcriptomic information is the Digital Spatial Profiler (DSP) system developed by Nanostring Technologies. This platform currently allows the quantitation of up to 50 proteins or thousands of genes in a small, user-defined region of interest, using formalin-fixed, paraffin-embedded (FFPE) tissue slices, while preserving the architecture of a tumor sample and without the need for additional sample collection. Previous bulk transcriptomic approaches have had very limited success in distinguishing responders from nonresponders in GBM trials, and one reason is the high level of inter- and intratumoral heterogeneity within the immune component in these tumors.⁷⁴ Through the use of in situ proteomic or transcriptomic technologies, the community can begin addressing the subtler differences in protein expression in a highly localized region, thus allowing the effect of the immediate microenvironment to be observed.⁷⁵ Novel approaches, such as this, are needed in order to more fully

understand the behavior of the TME in GBM patients after recurrence or in response to therapy, particularly immunotherapy.

Key Points

- Develop and exploit novel, more powerful technologies that can provide high-resolution single-cell type analyses without disrupting the architectural context
- Define molecular changes that can distinguish responders from nonresponders in GBM clinical trials

Understanding GBM Immune Resistance by Learning From Brain Metastases

Metastatic tumors to the brain confer a dire prognosis with significantly worse outcomes than metastases to other organs. In melanoma, CNS metastases have an overall survival in months (mOS) of 2.5 months, compared with metastases to the liver and digestive tract (mOS 5.5 months), lung (mOS 13 months), or subcutaneous tissue and lymph nodes (mOS 20.8 months).⁷⁶ Several recent clinical trials have demonstrated that checkpoint blockade immunotherapy can induce objective clinical responses, and even complete responses, in selected patients with small, asymptomatic, and nonsteroid-dependent brain metastases.^{77,78} Thus, brain metastases of melanoma appear similarly responsive to immunotherapy as extracranial disease, possibly attributable to diminished integrity of the BBB compared to GBM and

thus permissive to the entry of cytotoxic T cells. In small numbers of patients with brain metastases from non-small cell lung cancer, objective responses were also achieved with single-agent PD-1 blockade, and further studies are ongoing in both groups of patients using novel combination therapies based on PD-1 with or without CTLA-4 blockade.⁷⁹ Despite these benefits with immunotherapy in tumors from immuno-responsive malignancies metastatic to the brain, we have not seen similar success with immunotherapy in primary brain tumors such as GBM, with failures of anti-PD1 therapy in Checkmate 143,² Checkmate 498, and Checkmate 548.⁸⁰ Such findings suggest that the intrinsic immune response directed to the tumor may dictate the efficacy of immunotherapy, and not necessarily the microenvironment. Thus, an understanding of the immunological mechanisms underlying the “seed and soil” hypothesis of metastasis may provide an explanation for the discrepancy in response to immunotherapy.⁸¹

Recent two reports compared the immune landscape of primary vs metastatic brain cancers using high throughput analyses.^{82,83} Concordantly with previous studies, they found TAMs dominated in gliomas (up to 80% of leukocytes) whereas lymphocytes were abundant in metastatic brain tumors (up to 50%). These studies consistently demonstrated that immune cell composition and their respective phenotypic and functional features are dependent on the disease type in the CNS.

The anti-tumor immune response directed toward brain metastases may critically involve the systemic priming of T-cell responses before the development of metastatic disease in the brain,⁸⁴ which may account for how extracranial metastases and brain metastases are rejected by the immune system following successful checkpoint blockade immunotherapy. Such findings suggest that inadequate antigen presentation by tumor-infiltrating DCs may be one




Fig. 4 Replication-competent viruses infect tumor cells and activate immune responses. As they lead to tumor cell cytotoxicity and spread an infection to surrounding tumor cells, innate immune cells, such as macrophages, are activated and release cytokines, inflaming the tumor microenvironment. Lysis of tumor cells is thought to improve antigen presentation and infiltration of activated effector T cells against tumor and viral antigens. This leads to durable antitumor responses (adapted from Chiocca et al.⁸⁶).

of the limiting factors for immunotherapy in primary brain tumors. A similar sensitivity and resistance to immunotherapy may also be intrinsic to the timing of treatment, as a survival benefit was demonstrated when PD-1 blockade was administered neoadjuvantly (before surgery) both in GBM⁷⁵ and extracranial solid tumors.^{85–89} A similar benefit was not shown in adjuvant-only administration of the same immunotherapy in mouse models.⁹⁰ Regardless, based on what we know about the anti-tumor immune response directed at brain metastases, a potential solution may be to facilitate extracranial priming with vaccines,⁹¹ CD40 agonists,⁹² toll-like receptor (TLR) agonists,⁹³ cytoreductive surgery,⁷⁵ or radiation⁹⁴ to maximize the efficacy of immunotherapy for GBM.

Key Points

- GBM does not respond to immunotherapy with the same success as metastatic brain tumors
- The limited response of GBM to immunotherapy may be dependent upon the seed (tumor subtype, tumor-intrinsic characteristics) and the soil (brain microenvironment)
- Priming of the immune system through surgery, radiation, extracranial CD40 agonists, extracranial TLR agonists, or vaccines may improve responses to checkpoint inhibition

Viral Therapy and Immunotherapy

Oncolytic viruses are genetically engineered or natural strains of viruses that can infect tumor cells, replicate, and “biodistribute through the tumor.” This creates an inflammatory environment in the tumor causing influx of neutrophils, natural killer cells, macrophages, B cells, and T cells. This may be the fastest way to convert an “immunologically naive” tumor-like GBM into an inflammatory hot tumor (Figure 4). Oncolytic viruses that kill tumor cells and release tumor antigens in this inflammatory environment can convert the tumor into an endogenous vaccine. Multiple clinical trials in GBM have been conducted with herpes, polio, measles, adenovirus, reovirus, and parvoviruses. In addition, oncolytic viruses can be combined with immunotherapies, such as checkpoint inhibitors.⁹⁵

Emerging data from preclinical and clinical studies suggest that viral replication and persistence do not always correlate with anti-tumor effect and patient outcome. In the mouse GBM model (C2TA) treated with an oncolytic herpes simplex virus (HSV) rQNestin-34.5, tumor volume reduction directly correlated with increased viral replication/infection and expansion of functional T cells against tumor and viral antigens.⁹⁷ On the other hand, the data from a Phase Ib clinical trial in patients with recurrent GBM treated with oncolytic HSV G207 virus in the neoadjuvant setting indicated poor viral replication but the presence of an inflammatory infiltrate (CD3⁺ T cells, CD8⁺ T cells, and macrophages) in the posttreatment resected tumor.⁹⁸ Tumor biopsies from the longest surviving patient from this trial showed high amounts of HSV antigen, viral DNA,

and RNA transcripts, suggesting active viral replication and biodistribution within the GBM tissue of this patient. In contrast, viral antigen was detected in other patients but without transcripts, indicating the absence of viral replication. It is not very clear if viral antigen persistence is beneficial to the anti-tumor response or would result in chronic antigen exposure.

Another line of evidence supporting viral replication, persistence, and immunostimulatory activity is the data from syngeneic GBM model with retroviral replicating vector (RRV) Toca511-mediated prodrug activator gene therapy in a syngeneic GBM model.^{99,100} These studies reported an increase in CD4⁺ T helper cells, CD8⁺ CTL, and a bystander effect of virus killing of MDSCs, TAMs, and monocytes. In early-phase clinical trials of Toca 511 in recurrent high-grade glioma patients, the responder population exhibited a direct correlation between viral replication, persistence, and inflammatory immune profile in the resected tumors. The resected tumors from responders had a higher frequency of activated memory CD4⁺ T cells and reduced accumulation of macrophages when compared to the nonresponders.¹⁰¹ These studies suggest that, in responders, viral therapy may synergize with immunotherapy.

The 3-year patient survival rates across different Phase I and II oncolytic viral therapy (replicating retrovirus,^{102,103} parvovirus,¹⁰⁴ poliovirus,¹⁰⁵ and adenovirus¹⁰⁶) are around 20%.⁹⁶ Does this survival statistic suggest that all responders are immunologically equal, and they will respond irrespective of the kind of oncolytic viral therapy used? Distinct virus-specific gene expression patterns were induced in infected tumor cells, suggesting a differential effect by different viruses on different tumors. This implies that it is possible to combine two or more different viruses in the same patient to achieve an additive or synergistic effect. A recent study¹⁰⁷ interrogated the impact of oncolytic measles virus on a panel of patient-derived xenograft lines by RNA sequencing and gene set enrichment analysis. A unique gene signature was identified that was predictive of response to measles virus, which suggests that it may be possible to select patients who would benefit from this therapy based on pretreatment gene signature analysis.

The standard of care treatment for GBM with radiation and TMZ induces myelotoxicity and lymphopenia, while corticosteroid use causes T-cell apoptosis and cytokine depletion. In fact, recent vaccine studies have shown deleterious effects of corticosteroids for induction of vaccine-specific T-cell responses.^{108,109} Likewise, corticosteroids may negatively impact outcomes in cancer patients treated with checkpoint inhibitors,¹¹⁰ and no usage of corticosteroids at baseline was associated with longer overall survival (OS) in recurrent GBM patients treated with nivolumab (CheckMate 143 trial).² However, radiation therapy and TMZ, if used judiciously, may theoretically synergize with viral therapy. Both these agents cause tumor lysis, cross-priming, an abscopal effect, depletion of Tregs, and rebound expansion of effector CD8⁺ T cells. The use of oncolytic parvovirus or measles virus together with radiation therapy has been demonstrated to have synergistic activity.^{111,112} Similarly, the antitumor effects of TMZ were enhanced when used in combination with Newcastle disease virus.¹¹³

There appears to be a need to keep patients on immunotherapy trials for longer time in order for effective anti-tumor immune responses to fully develop. Overall, the timeline for achieving partial response has been 1-2 years, and complete response may take about 3 years in the GBM patient population. For example, subgroup analysis from the Phase III trial with Toca 511 appears to support the need for patients to be on the trial for a longer period of time. There is also a need for better evaluation criteria to assess and monitor the efficacy of viral therapy. Pseudoprogression, necrosis, influx of T cells, and staining for residual virus (to indicate virus persistence) are some of the parameters to be considered in evaluating the outcome of virotherapy. Ideally, tissue biopsies should be attempted pre- and post-viral therapy to assess the biological impacts of the viral therapy. It is also important to perform preclinical mouse studies to systematically address questions arising from clinical trials, such as use of oncolytic virus in combination with steroids or bevacizumab, and to optimize the timing of checkpoint inhibitors when used in conjunction with viral therapy.

Key Points

- More in-depth understanding is needed in terms of viral replication, persistence, immunogenicity for each of the virus platforms
- Multiplexing oncolytic viral and vector-mediated gene therapy—by arming the virus or viral vector with cytokines, chemokines, and checkpoint inhibitors
- Preclinical studies should be performed to optimize the timing of checkpoint inhibitors when used in conjunction with viral therapy

Challenges for CARs and TCR (T-Cell Receptor) Therapy: Antigen Heterogeneity, Tumor Escape, and Trafficking

The key challenges for effective chimeric antigen receptor-engineered T cells (CAR-T cells) for GBM therapy include many of the topics that have been discussed above, including overcoming pathways of immunosuppression, addressing tumor heterogeneity, and promoting trafficking and infiltration into these highly invasive tumors. Investigators are exploring various strategies to boost the trafficking efficiency of CAR-T cells to GBM and other brain tumors. Given that GBM almost never metastasizes to extra-CNS organs, one approach has been to evaluate locoregional modes of CAR-T cell delivery, primarily intratumoral/intracavitary (ICT) and intracerebroventricular (ICV) administration. Such regional delivery modalities can help in bypassing some of the brain-specific anatomical barriers. Preclinical studies comparing routes of administration in orthotopic brain tumor models^{114–116} demonstrated that regional delivery of CAR-T cells (ICT and ICV) mediate superior antitumor activity and long-term survival benefit as compared to intravenous (IV) delivery.¹¹⁴ In

early-phase clinical trials, locoregional delivery of CAR-T cells via a reservoir catheter device has been shown to be well tolerated in patients with evidence of antitumor activity, as well as providing the opportunity of liquid biopsy to follow local therapy-dependent changes in the CNS. Locoregional delivery of CAR-T cells may improve trafficking and tumor infiltration, but additional studies addressing the expansion and persistence of T cells are needed to improve treatment efficacy. To date, clinical response to CAR-T cell therapy has been limited to rare individual cases,¹¹⁷ and several obstacles contribute to this therapeutic challenge.

First, GBM's remarkable heterogeneity in antigen expression provides a strong tumor defense against CAR-T cells designed to target one specific antigen. Indeed, antigen escape—or the escape of tumor cells through the lack or loss of the targeted antigen—has been a major cause of CAR-T cell treatments in GBM.¹¹⁸ In response to this challenge, CARs have been designed to perform multi-antigen recognition through either hardwired approaches such as tandem-CARs and dual-CAR designs, or configurable antigen recognition designs, such as convertible CARs and zipCARs.^{119–122} The latter designs increase antigen recognition capability by either sequential or simultaneous addition of scFv-adaptor molecules. The drawback of this approach is the requirement for multimolecular interaction, in which adaptor molecules must find T cells as well as tumor cells at the right place and time in order to have efficacy. Whether such multimolecular interactions will work in the clinical setting remains to be tested.

An alternative strategy to tackle heterogeneous antigenic landscape of the tumor is to engage endogenous immune responses and induce antigen spreading. This can be done by overexpressing molecules, such as CD40L, Flt3L, and CXCR4 antagonists, in therapeutic T cells. In this strategy, therapeutic T cells are designed to not only provide front-line attack but also activate endogenous immune cells, such as APCs, to amplify the anti-tumor response.

In addition to antigen heterogeneity leading to tumor escape, CAR-T cell therapy for GBM also faces challenges posed by a highly immunosuppressive TME that can either exclude T cells entirely, or render T-cell dysfunction despite tumor infiltration. To promote recruitment to and infiltration of tumor cells, T cells have been engineered with chemokine receptors that complement the chemokine profile of the tumor. CXCR1- or CXCR2-modified CAR-T cells have shown improved migration, persistence, and antitumor response in IL-8-producing orthotopic GBM models.¹²³ Additionally, the targeting of integrins and adhesion molecules on endothelial cells within the tumor ecosystem can potentially improve the intratumoral trafficking of therapeutic T cells.^{124,125} Altering the chemokine composition of the tumor using an armed oncolytic virus, such as RANTES-expressing adenovirus, is another approach for enhancing T-cell recruitment.¹²⁶

Upon entering the TME, T cells must contend with potent immunosuppressive factors such as TGF- β , which has been shown to promote T-cell exclusion and dysfunction in a variety of solid tumors.^{127,128} The blockade of immunosuppressive mediators, such as TGF- β , can promote a T-cell-inclusive TME that facilitates adoptive T-cell therapy

for GBM. A novel approach for combating immunosuppressive mediators in the TME is to convert them into activating signals for CAR-T therapy. Recent work by Chen and colleagues demonstrated the ability to engineer CARs responsive to soluble antigens, including immunosuppressive cytokines, such as TGF- β .¹²⁹ In particular, a CAR that recognizes the mature form of TGF- β and not the latent form has been shown to convert TGF- β into a potent activator of T-cell effector function.¹²⁹ In addition, the TGF- β CAR outcompetes endogenous receptor and blocks endogenous TGF- β signaling, and it inhibits the conversion of naïve CD4⁺ T cells into Tregs in the presence of TGF- β .¹³⁰ The TGF- β CAR itself does not trigger cytotoxicity, thus, it must be combined with a receptor that recognizes a surface-bound tumor antigen for direct tumor killing, potentially in the tandem-CAR or dual-CAR formats previously developed for the purpose of overcoming antigen escape.^{122,131}

Key Points

- Locoregional delivery of CAR-T cells can help in bypassing anatomical barriers involved in trafficking from circulation
- Strategies are needed to engineer T cells such that they are resistant to suppressive TME or target multiple antigens to overcome tumor heterogeneity, as well as rational combination with other agents that promote CAR-T-cell function and/or endogenous immune response, are likely needed to unleash the full potential of CAR therapy for GBM

Lack of Adequate Imaging Technologies

Imaging is the standard noninvasive technique to measure the response to therapy in the absence of a biomarker to assess tumor progression or regression. However, early discrimination of pseudoprogression (inflammatory enlargement mimicking tumor growth) from disease progression remains a clinical challenge.^{132,133}

Attempts to address the limitations of conventional MRI and the RANO (Response Assessment in Neuro-Oncology) criteria in the setting of immunotherapy have been made through the mRANO¹³⁴ and iRANO criteria.¹³⁵ The mRANO criteria take into account pseudoresponse from bevacizumab/steroids and pseudoprogression from treatment-related changes through standardization of imaging acquisition with the international brain tumor imaging protocol (BTIP), consideration of lesion volume rather than bi-dimensional measurements, and the use of the postsurgical MRI as baseline to assist in clinical trial stratification during randomization. The iRANO criteria propose that within the first 6 months of initiation of an immunotherapy, therapy may be continued with repeat surveillance MRIs in 3 months or less, if the patient remains clinically stable or improved.

Several advanced MRI techniques show promise in delineating responses to therapy.¹³² Perfusion MRI through dynamic susceptibility contrast imaging, dynamic contrast-enhanced imaging, and arterial spin labeling add value in determining progression vs pseudoprogression. However, perfusion may be confounded by factors, such as tumor

vascularity (transfer coefficient k^{trans}) or fever which may increase cerebral blood volume to an area.

Diffusion-weighted sequencing characterizes the high cell density of tumor. However, immune infiltration into a tumor may likewise increase density. Additionally, postoperative cellular injury in the setting of surgical trauma, vascular injury, or devascularization of tumor may contribute to diffusion restriction.¹³⁶

The labeling of DCs with iron oxide or indium may noninvasively evaluate the fate of adoptively transferred cells.^{137,138} However, detrimental effects on cell viability, migration, differentiation, and immune function have limited its use in cellular imaging.¹³⁹ Further investigation in advanced MRI techniques may explore changes in diffusion characteristics of other lymphoid organs, such as the spleen or lymph nodes to infer systemic immune responses to immunotherapy.^{140,141}

The limitations of anatomic imaging have spurred the exploration and development of novel imaging techniques, including magnetic resonance spectroscopy (MRS), metabolic pH with chemical exchange saturation transfer (CEST), and novel positron emission tomography (PET) probes.^{142,143}

MRS allows for the noninvasive measurement of metabolites to help improve the diagnostic value of conventional MRI. By measuring isotopes of ¹H, ¹³C, or ³¹P, it is possible to correlate derangements in concentrations of metabolites with tumor grade.¹⁴⁴ Identification of metabolites of immunotherapy or inflammation may provide a marker to identify pseudoprogression.

CEST is a noninvasive pH-weighted modality that characterizes tissue acidosis via amine protons on glutamine from abnormal tumor perfusion and metabolism. Acidic signatures in malignant GBM correlate with histology of active and pseudopalisading tumor, perfusion abnormalities, lactate on MRS, and elevated FDOPA PET uptake.¹⁴⁵ Even in the setting of bevacizumab use, residual or emerging regions of acidity predicted areas of tumor progression.¹⁴⁶

Amino acid PET has been evaluated in brain tumors, with preliminary positive results with ¹¹C-methyl-L-methionine (MET), O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET), and 3,4-dihydroxy-6-6-[¹⁸F]-fluoro-L-phenylalanine (FDOPA).^{147,148} The mechanism appears to be mediated by increased transport of large neutral amino acids through transport systems LAT1 and LAT2.

PET may also be used to evaluate tumor markers such as PD-(L)1. In a first-in-human evaluation of non-small cell

Key Points

- The challenge of distinguishing pseudoprogression from progression leads to the early removal of patients from studies, curtailing our ability to evaluate the long-term benefits of immunotherapy
- Advanced MRI techniques including perfusion MRI, diffusion-weighted MRI, and iron-oxide or indium-labeled MRI may help to improve diagnostic decision-making
- The limitations of anatomic imaging have spurred exploration and development of novel imaging techniques, including MRS, metabolic pH with CEST, and novel PET probes




Fig. 5 Neoadjuvant trial design schema. A factorial approach facilitates the simultaneous evaluation of several combinations of agents (Drug X + placebo, Drug Y + placebo, placebo + placebo, Drug X + Drug Y). By applying a therapy and then undergoing resection to obtain tissue, neoadjuvant studies provide a systematic method of isolation of pharmacodynamics, immune, and clinical effects of treatment.

lung cancer, Zirconium-labeled nivolumab, and Fluor-labeled anti-PD-L1 Adnectin were successfully used to image PD-(L)1 expression of tumors and could be correlated with response to therapy.¹⁴⁹ However, there exist limitations in intracranial PET-tracer uptake secondary to the BBB.¹⁵⁰

The efficient access to and sharing of imaging remains a considerable challenge. By streamlining the ability to share data, it is possible to harness the power of advanced imaging in large trials to address questions, such as the impact of immune-related inflammation on survival. By leveraging radiomics and artificial intelligence to ground image analysis in pathology and immunological profiles, it may be possible to finally use imaging to identify pseudoprogression and predict response.^{151–153}

Preclinical Models

While adoptive T-cell therapies, such as TCR-transgenic and CAR-T cells, can be studied in xenograft models using established human cell lines or patient-derived xenografts in immunocompromised mice, most immunotherapies modulating the endogenous immune system require novel syngeneic mouse glioma cell lines, such as SB28.^{154,155} SB28 cells present clinically relevant characteristics, such as the low level of mutation load similar to human GBM, invasive growth and resistance to PD-1 and CTLA-4 double blockade therapy.¹⁵⁴ While de novo genetically engineered mouse models more thoroughly recapitulate genetic lesions found in human gliomas, to study therapies directed against human glioma neopeptides, mice with a human MHC system have been established.^{22,156} There is

an increasing availability of patient avatar models, where mice are reconstituted with a human immune system. Although these models in principle can more faithfully predict response to immunotherapies for individual patients, they are complex and require more extensive efforts and time to derive information for individual treatment decisions. While these models should be utilized more extensively in a variety of preclinical evaluations, the limitations emphasize the need for thoroughly designed, biomarker-driven clinical trials.

Clinical Trial Design

At least 50 clinical trials have evaluated immune-mediated therapies for GBM since 1997.¹⁵⁷ However, nearly all have failed in a randomized Phase III context. Immunological rejection of tumor cells requires a complete cascade of immune mechanisms, including antigen presentation, activation, and tumor-homing of effector cells as well as mitigation of immunosuppression. As such, the field recognizes the strong need of rational combination regimens. We would like to stress that, when we design combination regimens, it is critical to validate that each of the therapeutic agents has adequate levels of intended biological activities even if the agent did not show therapeutic efficacy as monotherapy. For example, if a vaccine is combined with a checkpoint blockade agent, the vaccine itself should be able to induce robust expansion of antigen-specific effector cells. It is therefore important to critically review biological data from relevant early-phase studies.

To effectively measure immunologic outcomes in small cohorts of patients, it is necessary to develop a complex




Fig. 6 The roadmap.

and coordinated process in the form of smartly designed clinical trials.

Critical issues in the clinical evaluation of immunotherapies include: (1) appropriate clinical trial design, (2) establishment of dosing, timing, and sequencing of therapy, (3) identification of immunological baselines, (4) determination of time points for evaluation, and (5) development of relevant biomarkers for future interventions.

The factorial approach in clinical trial design allows for a randomized, multiple-arm study evaluating a combination of several therapies simultaneously and efficiently.¹⁵⁸ Given the urgent need for effective therapies, the factorial approach lends to efficiency—but potentially at the cost of loss of statistical power, inability to account for unexpected synergistic interactions of therapies, and variability due to intra-patient or inter-patient changes in dosing.^{159,160} The first Phase II factorial study in newly diagnosed GBM involved 8 arms with 20 participants per arm. The primary objective compared the efficacy of adjuvant TMZ to adjuvant TMZ plus up to three additional agents (isotretinoin, celecoxib, and/or thalidomide). The secondary objective compared individual arms and doublet vs triplet therapy.¹⁶¹ Perhaps more importantly, this seminal investigation established the feasibility of factorial clinical trials in neuro-oncology.

Neoadjuvant studies provide a systematic method of evaluating hypotheses regarding mechanisms and

biology (Figure 5). By applying a therapy and then undergoing resection to obtain tissue, neoadjuvant studies make possible the ability to isolate and distinguish immune effects from treatment and develop specific biomarkers to evaluate the effects in future interventions.⁷⁵ Furthermore, neoadjuvant perturbations may isolate immune pharmacodynamic effects, and evaluations of combinations of therapies may provide regulatory implications by attributing clinical effects to combinations. The optimal time points for evaluation remain incompletely characterized. For initial anti-tumor effects, the immune response peaks between 1-3 weeks. For adaptive resistance, longitudinal re-sampling will be necessary.¹⁶² It is also paramount to keep in mind that early biological effects may not necessarily parallel late clinical effects. The baseline immune landscape and precise dosing, timing, and sequencing of therapies warrant further investigation.

Through a globally coordinated effort, we are able to ask and answer questions faster in patients.¹⁶³ The GBM Adaptive Global Innovative Learning Environment (GBM AGILE),¹⁶³ Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHT),¹⁶⁴ and the NCT Neuro Master Match^{165,166} are novel, multi-arm, platform trials using Bayesian adaptively randomized screening to identify the treatment arm with the most promising effect on OS compared to a common control, while balancing clinical factors and biomarkers. This design makes it possible to seamlessly add or drop experimental arms as patient

accrual continues. As we design clinical trials and discover biomarkers, it will be important to biobank cerebrospinal fluid, serum, plasma, and tissue for comparisons across multiple treatments and over time in a longitudinal evaluation.

Key Points

- Clinical trials involving a factorial design allow for the simultaneous evaluation of multiple therapies at once
- The GBM AGILE, INSIGHT, and the NCT Neuro Master Match represent the next wave of smartly designed clinical trials
- Window-of-opportunity, neoadjuvant Phase 0 studies provide a systematic method of evaluating therapeutic mechanisms

Conclusions and Moving Forward

The Think Tank meeting provided unique and privileged opportunities in which investigators in CNS and non-CNS tumor and immunology fields had problem-oriented discussions and shared novel insights that can be evaluated in CNS tumors. Moving forward, novel technologies in the assessment of TME and cell engineering, such as CAR-T cells, should be integrated with other important aspects that we discussed in this meeting, such as innovative clinical trial design and imaging. To further develop our discussions and accelerate clinical translation, future meetings of this series should include representatives of other areas, including but not limited to industry and regulatory agencies.

The Roadmap

Most importantly, taking valuable insights from this roundtable, we propose a roadmap to assist future studies to accelerate progress and collaborations. In particular, this revolves around six issues that need to be addressed concurrently (Figure 6):

- (1) A comparison between the anti-tumor immune response in successfully treated extracranial solid tumors should help the brain tumor field better understand what is lacking or missing in GBM patients treated with immunotherapy.
- (2) New high-dimensional technologies, both using single-cell data and in situ, should provide our field a more complete understanding of the immune cell types present within GBM and can be compared with new data from extracranial malignancies.
- (3) While we should continue extending our understanding on these issues, we already know some of the unique challenges of CNS cancers, such as BBB and blood-tumor barrier. We must enhance our engineering efforts by collaborating with relevant experts to develop more effective T-cell and antibody-based therapies, for example. These efforts should be integrated with considerate trial designs with the window of opportunity.
- (4) Properly designed early-phase “window of opportunity” clinical trials in patients can yield an enormous amount of new information regarding how discrete immunotherapies influence the microenvironment of GBM.
- (5) Collaborative ventures and the sharing of primary data between investigators can help to speed the understanding of how different immunotherapeutic interventions alter the anti-tumor immune response.
- (6) Finally, the development of a regulatory group to help offer many of the new immunotherapeutic agents, frequently restricted to patients with extracranial tumors, could dramatically enhance the scientific understanding of the anti-tumor immune response in brain tumor patients.

Funding

National Institute of Neurological Disorders and Stroke R35 NS105068-01(H.O.), National Cancer Institute P50CA211015 (R.M.P.).

Acknowledgments

The authors thank the Society for Neuro-Oncology and their Staff for their tremendous contributions to the arrangements and coordination for the meeting.

Authorship statement. Writing and editing of the original manuscript by all authors. Revision by P.C., F.C., P.B.W., M.G., M.P., R.M.P., and H.O. We declare no parts of the manuscript have been previously published or submitted concurrently to any other journal and all co-authors have read and approved of its submission to this journal.

Conflicts of interest statement. Y.C.: an inventor on a patent related to the TGF-beta CAR technology discussed in the publication. E.A.C.: currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., DNatrix Inc., Immunomic Therapeutics, Sangamo Therapeutics, Seneca Therapeutics and has equity interest in DNatrix, Immunomic Therapeutics, Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1 and non-coding RNAs. R.A.D.: founder, director, and/or advisor of Tvardi Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, Asyilia Therapeutics, and Sporos Bioventures. B.M.E.: For Profits—Medicenna—Paid Consultant—Significant (>\$20k), MedQIA, LLC—Paid Consultant, Ad Board, Neosoma—Paid Consultant, Agios Pharmaceuticals—Paid Consultant, Ad Board,

Siemens—Paid Consultant, Research Grant, Ad Board, Janssen Pharmaceuticals—Research Grant, Imaging Endpoints—Paid Consultant, Kazia/Novogen—Paid Consultant, Ad Board, VBL—Research Grant, NW Biopharmaceuticals—Paid Consultant, Ad Board, Oncoceutics Inc.—Consultant, BeiGene—Consultant, BBI—Consultant, Tocagen—Consultant; Non-Profits: Global Coalition for Adaptive Research (GCAR)—Consultant, NIH/NCI Cancer Imaging Steering Committee—Paid Consultant, National Brain Tumor Society—Research Grant, American Cancer Society—Research Grant. J.R.H.: the founder and board member of the following companies: Indi Molecular, PACT Pharma, Isoplexis, and Sofie Biosciences. A.B.H.: serves on the scientific advisory board of Caris Life Science and WCG Oncology Board, he received licensing fees from Celldex Therapeutics and DNatrix, received clinical trial funding from Merck and Celularity, and received study drug from Moleculin. N.K.: consultant for Abintus Bio, GenVivo, and SillaJen Biotherapeutics. L.M.L.: Consultant fees—JW Creagene, InSightec, Arbor Pharmaceuticals; Research grants to institution—Northwest Biotherapeutics, Merck. M.L.: Research Support—Arbor, BMS, Accuray, DNatrix, Tocagen, Biohaven, Kyron-Kyowa; Consultant—Tocagen, SQZ Technologies, VBI; CMO—Egret Therapeutics, Patent, Focused radiation + checkpoint inhibitors, Non-research Consultant – Stryker. E.W.N.: a co-founder, advisor, and shareholder of ImmunoScape Pte. Ltd. and an advisor for Neogene Therapeutics and Nanosting Technologies. H.O.: Consultant fees: Bristol-Myers Squibb, Agios Pharmaceuticals, Grant/Research support from: Agios Pharmaceuticals. Royalties as Inventor of: the H3.3K27M TCR, IL-13Ra2 (345-353:1A9V) peptide, and EGFRvIII-CAR for which an exclusive licensing agreement has been executed with Tmunity, Inc., Stemline, Inc., and Novartis Pharma, respectively. M.P.: reports non-financial support from Roche, personal fees and non-financial support from Bayer, personal fees from Novartis, personal fees from Apogenix, non-financial support from Pfizer, personal fees from Affiris outside the submitted work. In addition, M.P. has a patent EP2753315B1 licensed to Bayer, a patent EP2800580B1 issued, a patent US20180155403A1 pending, a patent US20180246118A1 pending, a patent US20170254803A1 pending, a patent WO2018146010A1 licensed to Bayer, a patent WO2019101643A1 licensed to Bayer, a patent WO2019101647A1 licensed to Bayer, a patent WO2019101641A1 licensed to Bayer, and a patent WO2019101642A1 licensed to Bayer. P.Y.W.: Research Support—Agios, Astra Zeneca/Medimmune, Beigene, Celgene, Eli Lilly, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Vascular Biogenics, VBI Vaccines; Advisory Board—Agios, Astra Zeneca, Bayer, Boston Pharmaceuticals, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, VBI Vaccines, Tocagen, Voyager, QED, Imvax, Elevate Bio; Speaker—Merck, Prime Oncology. All other authors declared none.

References

- Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. *J Immunother Cancer*. 2019;7(1):278.
- Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. *JAMA Oncol*. 2020;6(7):1003–1010.
- Weller M, Butowski N, Tran DD, et al.; ACT IV Trial Investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *Lancet Oncol*. 2017;18(10):1373–1385.
- Wen PY, Reardon DA, Armstrong TS, et al. A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with Glioblastoma. *Clin Cancer Res*. 2019;25(19):5799–5807.
- Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer*. Tocagen; 2019. <https://www.biospace.com/article/releases/tocagen-reports-results-of-toca-5-phase-3-trial-in-recurrent-brain-cancer/>
- Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. *Neuro Oncol*. 2015;17(Suppl 7):vii9–vii14.
- Goswami S, Walle T, Cornish AE, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. *Nat Med*. 2020;26(1):39–46.
- Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic analysis of immune cell infiltrates across 11 tumor types. *J Natl Cancer Inst*. 2016;108(11):djw144. <https://pubmed.ncbi.nlm.nih.gov/27335052/>
- Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. *Neuro Oncol*. 2016;18(2):195–205.
- de Groot J, Penas-Prado M, Alfaro-Munoz K, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. *Neuro Oncol*. 2020;22(4):539–549.
- Wei J, Chen P, Gupta P, et al. Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications. *Neuro Oncol*. 2019;22(2):180–194.
- Simoni Y, Becht E, Fehlings M, et al. Bystander CD8⁺ T cells are abundant and phenotypically distinct in human tumour infiltrates. *Nature*. 2018;557(7706):575–579.
- Duhen T, Duhen R, Montler R, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. *Nat Commun*. 2018;9(1):2724.
- Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. *Immunol Rev*. 2017;276(1):121–144.
- Gupta PK, Godec J, Wolinski D, et al. CD39 expression identifies terminally exhausted CD8⁺ T cells. *PLoS Pathog*. 2015;11(10):e1005177.
- Rosato PC, Wijeyesinghe S, Stolley JM, et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. *Nat Commun*. 2019;10(1):567.
- Zapatka M, Borozan I, Brewer DS, et al.; PCAWG Pathogens; PCAWG Consortium. The landscape of viral associations in human cancers. *Nat Genet*. 2020;52(3):320–330.
- Millar DG, Ramjiawan RR, Kawaguchi K, et al. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. *Nat Biotechnol*. 2020;38(4):420–425.
- Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T-cell dysfunction in Glioblastoma: applying a new framework. *Clin Cancer Res*. 2018;24(16):3792–3802.
- Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. *J Neurosurg*. 2019;131(3):657–666.
- Chongsathidkiet P, Jackson C, Koyama S, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. *Nat Med*. 2018;24(9):1459–1468.
- Bunse L, Pusch S, Bunse T, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. *Nat Med*. 2018;24(8):1192–1203.

23. Kohanbash G, Carrera DA, Shrivastav S, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8⁺ T cell accumulation in gliomas. *J Clin Invest*. 2017;127(4):1425–1437.
24. Thommen DS, Schumacher TN. T cell dysfunction in cancer. *Cancer Cell*. 2018;33(4):547–562.
25. Khan O, Giles JR, McDonald S, et al. TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. *Nature*. 2019;571(7764):211–218.
26. Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB. Innate immune functions of microglia isolated from human glioma patients. *J Transl Med*. 2006;4:15.
27. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. *J Neurosurg*. 1979;50(3):305–311.
28. Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. *Nat Rev Immunol*. 2018;18(4):225–242.
29. Gabrusiewicz K, Rodriguez B, Wei J, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. *JCI Insight*. 2016;1(2):e85841.
30. Müller S, Kohanbash G, Liu SJ, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. *Genome Biol*. 2017;18(1):234.
31. Bennett FC, Bennett ML, Yaqoob F, et al. A combination of ontogeny and CNS environment establishes microglial identity. *Neuron*. 2018;98(6):1170–1183.e78.
32. Viola A, Munari F, Sánchez-Rodríguez R, Scolaro T, Castegna A. The metabolic signature of macrophage responses. *Front Immunol*. 2019;10:1462.
33. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nat Med*. 1996;2(10):1096–1103.
34. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. *Cancer Res*. 2007;67(20):9630–9636.
35. Chang AL, Miska J, Wainwright DA, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. *Cancer Res*. 2016;76(19):5671–5682.
36. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. *Cancer Res*. 2011;71(7):2664–2674.
37. Thompson EA, Darrah PA, Foulds KE, et al. Monocytes acquire the ability to prime tissue-resident T cells via IL-10-mediated TGF- β release. *Cell Rep*. 2019;28(5):1127–1135.e24.
38. Chen P, Zhao D, Li J, et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. *Cancer Cell*. 2019;35(6):868–884.e66.
39. Chen P, Hsu WH, Chang A, et al. Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. *Cancer Discov*. 2020;10(3):371–381.
40. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. *Cancer Cell*. 2017;31(5):711–723.e14.
41. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? *Trends Immunol*. 2007;28(1):12–18.
42. Fischer HG, Bonifas U, Reichmann G. Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with *Toxoplasma gondii*. *J Immunol*. 2000;164(9):4826–4834.
43. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. *J Immunol*. 2001;166(4):2717–2726.
44. D'Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K. Brain dendritic cells: biology and pathology. *Acta Neuropathol*. 2012;124(5):599–614.
45. Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. *Neuroscience*. 1996;74(2):599–608.
46. King GD, Muhammad AK, Larocque D, et al. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. *Mol Ther*. 2011;19(10):1793–1801.
47. Flores C, Pham C, Snyder D, et al. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. *Oncoimmunology*. 2015;4(3):e994374.
48. Flores CT, Wildes TJ, Drake JA, et al. Lin-CCR2⁺ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. *Nat Commun*. 2018;9(1):4313.
49. Wakim LM, Woodward-Davis A, Bevan MJ. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. *Proc Natl Acad Sci U S A*. 2010;107(42):17872–17879.
50. Terabe M, Berzofsky JA. Tissue-specific roles of NKT cells in tumor immunity. *Front Immunol*. 2018;9:1838.
51. Yeh SC, Wang PY, Lou YW, et al. Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity. *Proc Natl Acad Sci U S A*. 2016;113(20):5592–5597.
52. Giussani P, Bassi R, Anelli V, et al. Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and paclitaxel. *Cancer Invest*. 2012;30(1):27–37.
53. Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-V α 14J α 18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. *J Exp Med*. 2005;202(12):1627–1633.
54. Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. *Nat Immunol*. 2011;12(9):870–878.
55. Wainwright DA, Balyasnikova IV, Chang AL, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. *Clin Cancer Res*. 2012;18(22):6110–6121.
56. Zhai L, Ladomersky E, Lenzen A, et al. IDO1 in cancer: a Gemini of immune checkpoints. *Cell Mol Immunol*. 2018;15(5):447–457.
57. Ladomersky E, Scholtens DM, Kocherginsky M, et al. The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma. *Front Pharmacol*. 2019;10:200.
58. Ladomersky E, Zhai L, Gritsina G, et al. Advanced age negatively impacts survival in an experimental brain tumor model. *Neurosci Lett*. 2016;630:203–208.
59. Opitz CA, Litzenburger UM, Sahn F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature*. 2011;478(7368):197–203.
60. Long GV, Dummer R, Hamid O, et al. Epcadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. *Lancet Oncol*. 2019;20(8):1083–1097.
61. Terabe M, Robertson FC, Clark K, et al. Blockade of only TGF- β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. *Oncoimmunology*. 2017;6(5):e1308616.
62. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. *Nat Immunol*. 2000;1(6):515–520.
63. Terabe M, Ambrosino E, Takaku S, et al. Synergistic enhancement of CD8⁺ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor- β monoclonal antibody. *Clin Cancer Res*. 2009;15(21):6560–6569.

64. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. *J Exp Med*. 2003;198(11):1741–1752.
65. Wick A, Desjardins A, Suarez C, et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. *Invest New Drugs*. 2020;38(5):1570–1579.
66. Brandes AA, Carpentier AF, Kesari S, et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. *Neuro Oncol*. 2016;18(8):1146–1156.
67. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science*. 2015;348(6230):69–74.
68. Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. *Immunity*. 2018;48(4):812–830.e14.
69. Dutoit V, Herold-Mende C, Hilf N, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. *Brain*. 2012;135(Pt 4):1042–1054.
70. Dutoit V, Migliorini D, Ranzanici G, et al. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. *Oncimmunology*. 2018;7(2):e1391972.
71. Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. *Nature*. 2019;565(7738):240–245.
72. Dettling S, Stamova S, Warta R, et al. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as novel and frequent T-cell targets in human IDH-mutant glioma. *Clin Cancer Res*. 2018;24(12):2951–2962.
73. Rapp C, Warta R, Stamova S, et al. Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. *Acta Neuropathol*. 2017;134(2):297–316.
74. Martinez-Lage M, Lynch TM, Bi Y, et al. Immune landscapes associated with different glioblastoma molecular subtypes. *Acta Neuropathol Commun*. 2019;7(1):203.
75. Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. *Nat Med*. 2019;25(3):477–486.
76. Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. *J Med Life*. 2014;7(4):572–576.
77. Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. *N Engl J Med*. 2018;379(8):722–730.
78. Tawbi HAH, Forsyth PAJ, Hodi FS, et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). *J Clin Oncol*. 2019;37(15).
79. Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. *Lancet Oncol*. 2020;21(5):655–663.
80. Reardon DA, Omuro A, Brandes AA, et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. *Neuro Oncol*. 2017;19(suppl_3):iii21.
81. Liu Y, Kosaka A, Ikeura M, et al. Premetastatic soil and prevention of breast cancer brain metastasis. *Neuro Oncol*. 2013;15(7):891–903.
82. Friebel E, Kapolou K, Unger S, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. *Cell*. 2020;181(7):1626–1642.e20.
83. Klemm F, Maas RR, Bowman RL, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. *Cell*. 2020;181(7):1643–1660.e17.
84. Taggart D, Andreou T, Scott KJ, et al. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8⁺ T cell trafficking. *Proc Natl Acad Sci U S A*. 2018;115(7):E1540–E1549.
85. Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, et al. Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control. *Oncologist*. 2019;24(5):671–679.
86. Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med*. 2018;24(11):1649–1654.
87. Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat Med*. 2018;24(11):1655–1661.
88. Forde PM, Chaft JE, Pardoll DM. Neoadjuvant PD-1 blockade in resectable lung cancer. *N Engl J Med*. 2018;379(9):e14.
89. O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. *Clin Cancer Res*. 2019;25(19):5743–5751.
90. Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. *Cancer Discov*. 2016;6(12):1382–1399.
91. Jackson CM, Kochel CM, Nirschl CJ, et al. Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. *Clin Cancer Res*. 2016;22(5):1161–1172.
92. Vonderheide R. The immune revolution: a case for priming, not checkpoint. *Cancer Cell*. 2019;33(4):563–569.
93. Bhardwaj N, Gnjatic S, Sawhney NB. TLR agonists: are they good adjuvants? *Cancer J*. 2011;16(4):382–391.
94. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? *Nat Rev Clin Oncol*. 2017;14(6):365–379.
95. Passaro C, Alayo Q, De Laura I, et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. *Clin Cancer Res*. 2019;25(1):290–299.
96. Chiocca EA, Nassiri F, Wang J, Peruzzi P, Zadeh G. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? *Neuro Oncol*. 2019;21(1):14–25.
97. Alayo QA, Ito H, Passaro C, et al. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. *Sci Rep*. 2020;10(1):5095.
98. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. *Mol Ther*. 2009;17(1):199–207.
99. Hiraoka K, Inagaki A, Kato Y, et al. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. *Neuro Oncol*. 2017;19(7):918–929.
100. Mitchell LA, Lopez Espinoza F, Mendoza D, et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. *Neuro Oncol*. 2017;19(7):930–939.
101. Accomando WP, Cloughesy T, Kalkanis S, et al. Immunologic trends associated with patient outcomes in a phase 1 clinical trial of Toca 511 and Toca FC in recurrent high grade glioma. *Neuro Oncol*. 2018;20(suppl_6):vi6–vi7.

102. Cloughesy TF, Landolfi J, Hogan DJ, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. *Sci Transl Med.* 2016;8(341):341ra375.
103. Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. *Neuro Oncol.* 2018;20(10):1383–1392.
104. Geletneký K, Hajda J, Angelova AL, et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first Phase I/IIa glioblastoma trial. *Mol Ther.* 2017;25(12):2620–2634.
105. Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. *N Engl J Med.* 2018;379(2):150–161.
106. Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. *J Clin Oncol.* 2018;36(14):1419–1427.
107. Kurokawa C, Iankov ID, Anderson SK, et al. Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy. *J Natl Cancer Inst.* 2018;110(10):1123–1132.
108. Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. *Nature.* 2019;565(7738):234–239.
109. Mueller S, Taitt JM, Villanueva-Meyer JE, et al. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. *J Clin Invest.* 2020;130(12):6325–6337.
110. Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. *Cancers (Basel).* 2020;12(3).
111. Geletneký K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection. *J Biomed Biotechnol.* 2010;2010:350748.
112. Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. *Clin Cancer Res.* 2007;13(23):7155–7165.
113. Bai Y, Chen Y, Hong X, et al. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. *Sci Rep.* 2018;8(1):11470.
114. Brown CE, Aguilar B, Starr R, et al. Optimization of IL13R α 2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. *Mol Ther.* 2018;26(1):31–44.
115. Priceman SJ, Tilakawardane D, Jeang B, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2⁺ breast cancer metastasis to the brain. *Clin Cancer Res.* 2018;24(1):95–105.
116. Theruvath J, Sotillo E, Mount CW, et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. *Nat Med.* 2020;26(5):712–719.
117. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. *N Engl J Med.* 2016;375(26):2561–2569.
118. O'Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci Transl Med.* 2017;9(399):eaaa0984.
119. Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. *Cell.* 2018;173(6):1426–1438.e11.
120. Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. *Mol Ther Nucleic Acids.* 2013;2:e105.
121. Herzig E, Kim KC, Packard TA, et al. Attacking latent HIV with convertible CAR-T Cells, a highly adaptable killing platform. *Cell.* 2019;179(4):880–894.e10.
122. Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. *Cancer Immunol Res.* 2016;4(6):498–508.
123. Jin L, Tao H, Karachi A, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. *Nat Commun.* 2019;10(1):4016.
124. Sasaki K, Zhu X, Vasquez C, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. *Cancer Res.* 2007;67(13):6451–6458.
125. Zhu X, Nishimura F, Sasaki K, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. *J Transl Med.* 2007;5:10.
126. Nishio N, Dotti G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. *Oncoimmunology.* 2015;4(2):e988098.
127. Mariathasan S, Turley SJ, Nickles D, et al. TGF β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature.* 2018;554(7693):544–548.
128. Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGF β drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature.* 2018;554(7693):538–543.
129. Chang ZL, Hou AJ, Chen YY. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands. *Nat Protoc.* 2020;15(4):1507–1524.
130. Hou AJ, Chang ZL, Lorenzini MH, Zah E, Chen YY. TGF- β -responsive CAR-T cells promote anti-tumor immune function. *Bioeng Transl Med.* 2018;3(2):75–86.
131. Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. *Nat Commun.* 2020;11(1):2283.
132. Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. *J Neurooncol.* 2017;134(3):495–504.
133. Ranjan S, Quezado M, Garren N, et al. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. *BMC Cancer.* 2018;18(1):239.
134. Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. *Neurotherapeutics.* 2017;14(2):307–320.
135. Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. *Lancet Oncol.* 2015;16(15):e534–e542.
136. Smith JS, Cha S, Mayo MC, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. *J Neurosurg.* 2005;103(3):428–438.
137. Tavaré R, Sagoo P, Varama G, et al. Monitoring of in vivo function of superparamagnetic iron oxide labelled murine dendritic cells during anti-tumour vaccination. *PLoS One.* 2011;6(5):e19662.
138. Verdijk P, Scheenen TW, Lesterhuis WJ, et al. Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. *Int J Cancer.* 2007;120(5):978–984.
139. Dekaban GA, Snir J, Shrum B, et al. Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI. *J Immunother.* 2009;32(3):240–251.

140. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. *AJR Am J Roentgenol*. 2011;197(6):W992–W1000.
141. Tsai KK, Pampaloni MH, Hope C, et al. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. *J Immunother Cancer*. 2016;4:58.
142. Bensch F, van der Veen EL, Lub-de Hooge MN, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med*. 2018;24(12):1852–1858.
143. Pandit-Taskar N, Postow MA, Hellmann MD, et al. First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. *J Nucl Med*. 2020;61(4):512–519.
144. Bulik M, Jancalek R, Vanicek J, Koch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. *Clin Neurol Neurosurg*. 2013;115(2):146–153.
145. Harris RJ, Cloughesy TF, Liu LM, et al. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. *Neuro Oncol*. 2015;17(11):1514–1524.
146. Yao J, Tan CHP, Schlossman J, et al. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. *J Neurooncol*. 2019;142(3):587–595.
147. Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol*. 2016;18(9):1199–1208.
148. Galldiks N, Law I, Pope WB, Arbizu J, Langen KJ. The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. *Neuroimage Clin*. 2017;13:386–394.
149. Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. *Nat Commun*. 2018;9(1):4664.
150. Mayer AT, Natarajan A, Gordon SR, et al. Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. *J Nucl Med*. 2017;58(4):538–546.
151. Booth TC, Williams M, Luis A, Cardoso J, Ashkan K, Shuaib H. Machine learning and glioma imaging biomarkers. *Clin Radiol*. 2020;75(1):20–32.
152. Chaddad A, Kucharczyk MJ, Daniel P, et al. Radiomics in glioblastoma: current status and challenges facing clinical implementation. *Front Oncol*. 2019;9:374.
153. Elshafeey N, Kotrotsou A, Hassan A, et al. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. *Nat Commun*. 2019;10(1):3170.
154. Genoud V, Marinari E, Nikolaev SI, et al. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. *Oncoimmunology*. 2018;7(12):e1501137.
155. Kosaka A, Ohkuri T, Okada H. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. *Cancer Immunol Immunother*. 2014;63(8):847–857.
156. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumor immunity. *Nature*. 2014;512(7514):324–327.
157. Rajani KR, Carlstrom LP, Parney IF, Johnson AJ, Warrington AE, Burns TC. Harnessing radiation biology to augment immunotherapy for glioblastoma. *Front Oncol*. 2018;8:656.
158. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. *BMC Med Res Methodol*. 2003;3:26.
159. Green S, Liu PY, O'Sullivan J. Factorial design considerations. *J Clin Oncol*. 2002;20(16):3424–3430.
160. Iwamoto FM, Lassman AB. Factorial clinical trials: a new approach to phase II neuro-oncology studies. *Neuro Oncol*. 2015;17(2):174–176.
161. Penas-Prado M, Hess KR, Fisch MJ, et al.; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. *Neuro Oncol*. 2015;17(2):266–273.
162. GLASS Consortium. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. *Neuro Oncol*. 2018;20(7):873–884.
163. Alexander BM, Ba S, Berger MS, et al.; GBM AGILE Network. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. *Clin Cancer Res*. 2018;24(4):737–743.
164. Alexander B, Trippa L, Gaffey S, et al. Individualized screening trial of innovative glioblastoma therapy (INSIGHt). *J Clin Oncol*. 2017;35:TPS2079.
165. Pfaff E, Kessler T, Balasubramanian GP, et al. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study. *Neuro Oncol*. 2018;20(6):826–837.
166. Wick W, Dettmer S, Berberich A, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro Oncol*. 2019;21(1):95–105.